FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2169596181> ?p ?o ?g. }

• W2169596181 endingPage "3437" @default.
• W2169596181 startingPage "3431" @default.
• W2169596181 abstract "This Children's Cancer Group group-wide phase II trial evaluated the efficacy and toxicity of two chemotherapy arms administered before hyperfractionated external-beam radiotherapy (HFEBRT).Thirty-two patients with newly diagnosed brainstem gliomas were randomly assigned to regimen A and 31 to regimen B. Regimen A comprised three courses of carboplatin, etoposide, and vincristine; regimen B comprised cisplatin, etoposide, cyclophosphamide, and vincristine. Both arms included granulocyte colony-stimulating factor. Patients were evaluated by magnetic resonance imaging after induction chemotherapy and HFEBRT at a dose of 72 Gy.Ten percent +/- 5% of regimen A patients objectively responded to chemotherapy. For combined induction and radiotherapy, 27% +/- 9% of patients improved. The neuroradiographic response rate for regimen B was 19% +/- 8% for chemotherapy and 23% +/- 9% after HFEBRT. Response rates were not statistically significant between regimens after induction or chemotherapy/HFEBRT. Event-free survival was 17% +/- 5% (estimate +/- SE) at 1 year and 6% +/- 3% at 2 years. Survival was significantly longer among patients who responded to chemotherapy (P <.05). Among patients who received regimen A induction, grades 3 and 4 leukopenia were observed in 50% to 65%, with one toxicity-related death. For regimen B, severe leukopenia occurred in 86% to 100%, with febrile neutropenia in 48% to 60% per course.Neither chemotherapy regimen meaningfully improved response rate, event-free survival, or overall survival relative to previous series of patients with brainstem gliomas who received radiotherapy with or without chemotherapy." @default.
• W2169596181 created "2016-06-24" @default.
• W2169596181 creator A5000350921 @default.
• W2169596181 creator A5001167348 @default.
• W2169596181 creator A5002273605 @default.
• W2169596181 creator A5003312623 @default.
• W2169596181 creator A5003580675 @default.
• W2169596181 creator A5007291376 @default.
• W2169596181 creator A5008151347 @default.
• W2169596181 creator A5017658161 @default.
• W2169596181 creator A5020276596 @default.
• W2169596181 creator A5030658031 @default.
• W2169596181 creator A5041982604 @default.
• W2169596181 creator A5047701227 @default.
• W2169596181 creator A5052896867 @default.
• W2169596181 creator A5053141643 @default.
• W2169596181 creator A5061181330 @default.
• W2169596181 creator A5076645797 @default.
• W2169596181 creator A5077862095 @default.
• W2169596181 creator A5080784534 @default.
• W2169596181 creator A5084157591 @default.
• W2169596181 creator A5087263869 @default.
• W2169596181 date "2002-08-15" @default.
• W2169596181 modified "2023-09-26" @default.
• W2169596181 title "Preradiation Chemotherapy in Primary High-Risk Brainstem Tumors: Phase II Study CCG-9941 of the Children’s Cancer Group" @default.
• W2169596181 cites W1844473895 @default.
• W2169596181 cites W1966821677 @default.
• W2169596181 cites W1967964100 @default.
• W2169596181 cites W1997195777 @default.
• W2169596181 cites W2008455779 @default.
• W2169596181 cites W2015660037 @default.
• W2169596181 cites W2016681837 @default.
• W2169596181 cites W2017766609 @default.
• W2169596181 cites W2024815986 @default.
• W2169596181 cites W2025530313 @default.
• W2169596181 cites W2027570477 @default.
• W2169596181 cites W2040272758 @default.
• W2169596181 cites W2052505504 @default.
• W2169596181 cites W2059935943 @default.
• W2169596181 cites W2066458042 @default.
• W2169596181 cites W2072642410 @default.
• W2169596181 cites W2081987256 @default.
• W2169596181 cites W2085277801 @default.
• W2169596181 cites W2103594288 @default.
• W2169596181 cites W2136594231 @default.
• W2169596181 cites W2285560870 @default.
• W2169596181 cites W2334615503 @default.
• W2169596181 cites W25575551 @default.
• W2169596181 doi "https://doi.org/10.1200/jco.2002.04.109" @default.
• W2169596181 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12177103" @default.
• W2169596181 hasPublicationYear "2002" @default.
• W2169596181 type Work @default.
• W2169596181 sameAs 2169596181 @default.
• W2169596181 citedByCount "95" @default.
• W2169596181 countsByYear W21695961812012 @default.
• W2169596181 countsByYear W21695961812013 @default.
• W2169596181 countsByYear W21695961812014 @default.
• W2169596181 countsByYear W21695961812015 @default.
• W2169596181 countsByYear W21695961812016 @default.
• W2169596181 countsByYear W21695961812017 @default.
• W2169596181 countsByYear W21695961812018 @default.
• W2169596181 countsByYear W21695961812019 @default.
• W2169596181 countsByYear W21695961812020 @default.
• W2169596181 countsByYear W21695961812021 @default.
• W2169596181 countsByYear W21695961812022 @default.
• W2169596181 crossrefType "journal-article" @default.
• W2169596181 hasAuthorship W2169596181A5000350921 @default.
• W2169596181 hasAuthorship W2169596181A5001167348 @default.
• W2169596181 hasAuthorship W2169596181A5002273605 @default.
• W2169596181 hasAuthorship W2169596181A5003312623 @default.
• W2169596181 hasAuthorship W2169596181A5003580675 @default.
• W2169596181 hasAuthorship W2169596181A5007291376 @default.
• W2169596181 hasAuthorship W2169596181A5008151347 @default.
• W2169596181 hasAuthorship W2169596181A5017658161 @default.
• W2169596181 hasAuthorship W2169596181A5020276596 @default.
• W2169596181 hasAuthorship W2169596181A5030658031 @default.
• W2169596181 hasAuthorship W2169596181A5041982604 @default.
• W2169596181 hasAuthorship W2169596181A5047701227 @default.
• W2169596181 hasAuthorship W2169596181A5052896867 @default.
• W2169596181 hasAuthorship W2169596181A5053141643 @default.
• W2169596181 hasAuthorship W2169596181A5061181330 @default.
• W2169596181 hasAuthorship W2169596181A5076645797 @default.
• W2169596181 hasAuthorship W2169596181A5077862095 @default.
• W2169596181 hasAuthorship W2169596181A5080784534 @default.
• W2169596181 hasAuthorship W2169596181A5084157591 @default.
• W2169596181 hasAuthorship W2169596181A5087263869 @default.
• W2169596181 hasConcept C126322002 @default.
• W2169596181 hasConcept C141071460 @default.
• W2169596181 hasConcept C143998085 @default.
• W2169596181 hasConcept C2776611710 @default.
• W2169596181 hasConcept C2776694085 @default.
• W2169596181 hasConcept C2776755627 @default.
• W2169596181 hasConcept C2777063308 @default.
• W2169596181 hasConcept C2778119113 @default.
• W2169596181 hasConcept C2778239845 @default.
• W2169596181 hasConcept C2778336483 @default.
• W2169596181 hasConcept C2779429289 @default.
• W2169596181 hasConcept C2780873365 @default.

• next